Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab in severe eosinophilic asthma (AERFLO)
NCT03733535Active, not recruiting
- Sponsor
- Parraga Lab
- Start
- Mar 2022
- Primary completion
- Mar 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of benralizumab in eosinophilic asthma (EA), sponsored by Parraga Lab. Primary endpoint: Change from baseline airway function measured using 129-Xenon MRI ventilation defect percent at Day 28. Started Mar 2022; status: active, not recruiting.
02
Drugs
benralizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT03733535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03733535.